CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

详细信息    查看全文

• 作者：Luana Calabrò ; Giovanni Luca Ceresoli…
• 关键词：Mesothelioma ; Anti ; CTLA4 mAb ; Tremelimumab ; Immunotherapy ; NIBIT ; 2013
• 刊名：Cancer Immunology, Immunotherapy
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：64
• 期：1
• 页码：105-112
• 全文大小：1,214 KB
• 参考文献：1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89:716-24 CrossRef
  2. Ceresoli GL, Gridelli C, Santoro A (2007) Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 12:850-63 CrossRef
  3. Datta A, Smith R, Fiorentino F, Treasure T (2014) Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax 69:194-97 CrossRef
  4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-644 CrossRef
  5. Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756-63 CrossRef
  6. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, J?nne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509-515 CrossRef
  7. Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P (2013) Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 14:543-51 CrossRef
  8. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24-2 CrossRef
  9. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698-704 CrossRef
  10. Krug LM, Kindler H, Calvert H, VANTAGE 014 et al (2011) Vorinostat in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 47(Suppl 2):2- CrossRef
  11. Ceresoli GL, Zucali PA (2012) Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opin Investig Drugs 21:833-44 CrossRef
  12. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A (2011) Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 72:73-7 CrossRef
  13. Busacca S, Sheaff M, Arthur K, Gray SG, O’Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Path
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Immunology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0851

文摘

No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.